

What Is Claimed Is:

1. A combination comprising a therapeutically-  
5 effective amount of an angiotensin converting enzyme  
inhibitor and an epoxy-steroidal aldosterone receptor  
antagonist, said epoxy-steroidal aldosterone receptor  
antagonist being present in an amount which is  
therapeutically effective to antagonize aldosterone but  
10 which amount is not sufficient for said aldosterone  
receptor antagonist to induce a substantially adverse  
side effect.

2. The combination of Claim 1 wherein said  
15 aldosterone receptor antagonist is an epoxy-steroidal-  
type compound characterized in having a 9 $\alpha$ -,11 $\alpha$ -  
substituted epoxy moiety.

3. The combination of Claim 2 wherein said  
20 epoxy-steroidal-type compound is eplerenone.

4. The combination of Claim 1 wherein  
angiotensin converting enzyme inhibitor is selected from  
the group consisting of alacepril, benazepril, captopril,  
25 cilazapril, delapril, enalapril, enalaprilat, fosinopril,  
fosinoprilat, imidapril, lisinopril, perindopril,  
quinapril, ramipril, saralasin acetate, temocapril,  
trandolapril, ceranapril, moexipril, quinaprilat,  
spirapril, Bioproject BP1.137, Chiesi CHF 1514, Fisons  
30 FPL-66564, idrapril, Marion Merrell Dow MDL-100240,  
perindoprilat, and Servier S-5590.

5. The combination of Claim 4 wherein said  
angiotensin converting enzyme inhibitor is selected from  
35 the group consisting of alacepril, benazepril, captopril,  
cilazapril, delapril, enalapril, enalaprilat, fosinopril,  
fosinoprilat, imidapril, lisinopril, perindopril,  
quinapril, ramipril, saralasin acetate, temocapril,

trandolapril, ceranapril, moexipril, quinaprilat, and spirapril.

6. The combination of Claim 1 further  
5 characterized by said angiotensin converting enzyme  
inhibitor and said aldosterone receptor antagonist being  
present in said combination in a weight ratio range from  
about 0.5-to-one to about twenty-to-one of said  
angiotensin converting enzyme inhibitor to said  
10 aldosterone receptor antagonist.

7. The combination of Claim 6 wherein said  
weight ratio range is from about one-to-one to about  
fifteen-to-one.  
15

8. The combination of Claim 7 wherein said  
weight ratio range is from about one-to-one to about  
five-to-one.

20 9. A combination therapy for treating  
cardiovascular disorders in a subject afflicted with or  
susceptible to multiple cardiovascular disorders, wherein  
said combination therapy comprises administering a  
therapeutically-effective amount of a two-component  
25 combination consisting essentially of an angiotensin  
converting enzyme inhibitor as a first component and an  
epoxy-steroidal aldosterone receptor antagonist as a  
second component in an amount therapeutically effective  
to antagonize aldosterone but insufficient to induce an  
30 adverse side effect.

10. The combination therapy of Claim 9 wherein  
said subject is afflicted with or susceptible to heart  
failure and said subject further requires avoidance of  
35 the incidence of hyperkalemia.

11. The combination therapy of Claim 10 wherein said subject is further susceptible to congestive heart failure.

5           12. The combination therapy of Claim 10 wherein said subject is further susceptible to hypertension.

10           13. The combination therapy of Claim 10 further characterized by administering said angiotensin converting enzyme inhibitor and said epoxy-steroidal aldosterone receptor antagonist.

15           14. The combination therapy of Claim 10 further characterized by administering said angiotensin converting enzyme inhibitor and said epoxy-steroidal aldosterone receptor antagonist in a substantially simultaneous manner.

20           15. The combination therapy of Claim 9 wherein said epoxy-steroidal aldosterone receptor antagonist is a compound characterized in having a 9 $\alpha$ -11 $\alpha$ -substituted epoxy moiety.

25           16. The combination therapy of Claim 15 wherein said epoxy-steroidal compound is eplerenone.

30           17. The combination therapy of Claim 9 wherein said angiotensin converting enzyme inhibitor is selected from the group consisting of alacepril, benazepril, captopril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lisinopril, perindopril, quinapril, ramipril, saralasin acetate, temocapril, trandolapril, ceranapril, moexipril, 35   quinaprilat, spirapril, Bioproject BP1.137, Chiesi CHF 1514, Fisons FPL-66564, idrapril, Marion Merrell Dow MDL-100240, perindoprilat, and Servier S-5590.

18. The combination therapy of Claim 17 wherein said angiotensin converting enzyme inhibitor is selected from the group consisting of alacepril, benazepril, captopril, cilazapril, delapril, enalapril, 5 enalaprilat, fosinopril, fosinoprilat, imidapril, lisinopril, perindopril, quinapril, ramipril, saralasin acetate, temocapril, trandolapril, ceranapril, moexipril, quinaprilat, and spirapril.

10 19. The combination therapy of Claim 9 further characterized by said angiotensin converting enzyme inhibitor and said epoxy-steroidal aldosterone receptor antagonist being used in said co-therapy in a weight ratio range from about 0.5-to-one to about twenty-to-one 15 of said angiotensin converting enzyme inhibitor to said aldosterone receptor antagonist.

20 20. The combination therapy of Claim 19 wherein said weight ratio range is from about one-to-one to about fifteen-to-one.

25 21. The combination therapy of Claim 20 wherein said weight ratio range is from about one-to-one to about five-to-one.

22. The combination therapy of Claim 9 wherein said angiotensin converting enzyme inhibitor is captopril, in a dose range from about 40 mg to about 80 mg per dose, or is enalapril in a dose range from about 5 30 mg to about 25 mg per dose.

23. The combination therapy of Claim 22 wherein said epoxy-steroidal aldosterone receptor antagonist is eplerenone in a dose range from about 25 mg 35 to about 100 mg per dose.